Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gut microbiota community and intestinal barrier constitute a critical physiological interface responsible for maintaining systemic homeostasis and protecting the host from environmental insults (Thursby & Juge, 2017, Biochemical Journal). The intestinal barrier is a multi-layered structure composed of a mucus layer, a single layer of epithelial cells connected by tight junctions, and an underlying immune system, while the microbiota consists of a diverse ecosystem of bacteria, fungi, and viruses (Vancamelbeke & Vermeire, 2017, Therapeutic Advances in Gastroenterology). Together, they regulate nutrient absorption, synthesize essential metabolites like short-chain fatty acids, and educate the mucosal immune system to distinguish between commensal organisms and pathogens (Bischoff et al., 2014, BMC Gastroenterology). Disruptions in this delicate balance, often referred to as leaky gut or dysbiosis, are linked to the pathogenesis of various conditions, including inflammatory bowel disease, metabolic disorders, and autoimmune diseases (Fasano, 2011, Physiological Reviews). Therapeutic interventions focus on restoring microbial diversity and reinforcing barrier integrity through pharmacological agents like Rifaximin, dietary modifications, and microbial transfers (Ponziani et al., 2017, World Journal of Gastroenterology).
Modulation of microbial diversity, enhancement of tight junction protein expression (e.g., zonulin, occludin), and production of anti-inflammatory metabolites like short-chain fatty acids (SCFAs) (Bischoff et al., 2014, BMC Gastroenterology).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiota community and intestinal barrier.